Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Matignon Technologies

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 9
Average round size
info
The average size of a deal this fund participated in
$7M
Portfolio companies 7
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.22
Exits 1
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical Device
  • Manufacturing
  • Medical
Summary

The leading representative office of defined VC is situated in the Paris. The venture was found in Europe in France.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Matignon Technologies, startups are often financed by Societe Generale Asset Management, MDS Capital, Charleston Angel Partners. The meaningful sponsors for the fund in investment in the same round are Societe Generale Asset Management, MDS Capital, MB Venture Partners. In the next rounds fund is usually obtained by Ridgeback Capital, Kensey Nash Corporation, InnoBio Fund.

Among the most popular fund investment industries, there are Manufacturing, Health Care. For fund there is a match between the country of its foundation and the country of its the most frequent investments - France. Among the various public portfolio startups of the fund, we may underline Orteq, Arterial Remodeling Technologies Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.

The fund is generally included in less than 2 deals every year. The high activity for fund was in 2007. Comparing to the other companies, this Matignon Technologies performs on 4 percentage points less the average number of lead investments. Speaking about the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 5 - 10 millions dollars.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Matignon Technologies:
Typical Co-investors
Matignon Technologies is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Matignon Technologies:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from France
Funds with similar focus located in France:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Charity Deposits Corporation Florida, Miami, United States
Farm Capital Africa -
iVentures Asia Ltd China, Hong Kong, Hong Kong Island
Krungsri Finnovate Bangkok, Krung Thep, Thailand
Latham & Watkins California, Los Angeles, United States
Lite-On Technology Taipei, Taiwan
Maritz Fenton, Missouri, United States
Nanto Lease Japan, Nara, Nara Prefecture
Office Depot Boca Raton, Florida, United States
Ollerhead Capital -
Residentie Investments The Netherlands, Utrecht, Zeist
Shenzhenshi Jiruihe Guquan Touzi China, Guangdong, Shenzhen
Shixiangjia New Media Fund China, Hangzhou, Zhejiang
Softhouse -
Studio VC New York, New York, United States
Techstars Starburst Space Accelerator California, Los Angeles, United States
the Long Island Emerging technologies Fund (LIETF) Melville, New York, United States
Yunshan Ziben China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Nanobiotix

Biotechnology
Health Care
Therapeutics
$8M05 May 2010 Paris, Ile-de-France, France

Biotechnology
Health Care
Manufacturing
Medical
Medical Device
Sports
Wellness
$10M07 Oct 2008 England

AirInSpace

Biotechnology
Health Care
Manufacturing
$8M08 Oct 2007 France, Ile-de-France

Gentis

Biotechnology
Health Care
Manufacturing
Medical
Medical Device
Wellness
$10M21 Jun 2007 Radnor Township, Pennsylvania, United States

Health Care
$2M30 Mar 2007 Bethlehem, Pennsylvania, United States

Alveolus

$10M30 Jul 2004 -

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Matignon Technologies?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 9
Average round size 7M
Peak activity year 2007
Lead investments 3
Follow on index 0.22
Exits 1
Group Appearance index 0.67

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Nanobiotix

Biotechnology
Health Care
Therapeutics
$8M05 May 2010 Paris, Ile-de-France, France

Biotechnology
Health Care
Manufacturing
Medical
Medical Device
Sports
Wellness
$10M07 Oct 2008 England

AirInSpace

Biotechnology
Health Care
Manufacturing
$8M08 Oct 2007 France, Ile-de-France

Gentis

Biotechnology
Health Care
Manufacturing
Medical
Medical Device
Wellness
$10M21 Jun 2007 Radnor Township, Pennsylvania, United States

Health Care
$2M30 Mar 2007 Bethlehem, Pennsylvania, United States

Alveolus

$10M30 Jul 2004 -
Crunchbase icon

Content report

The following text will be sent to our editors: